(From left) Tan, AffinHwang IB deputy managing director Yip Kit Weng, Optimax non-independent non-executive director Datuk Tan Boon Hock, chief financial officer Michelle Tan and senior medical director Dr Stephen Chung during the prospectus launch yesterday.
KUCHING: Optimax Holdings Bhd (Optimax), an established private eye specialist service provider, launched its prospectus yesterday for its listing on the ACE Market of Bursa Malaysia Securities Berhad.
The initial public offering (IPO) entails a public issue of 70 million IPO shares at the issue price of RM0.30 per share.
A total of 13.50 million shares will be made available for the Malaysian public; four million shares by eligible directors and employees of Optimax; and 52.50 million shares by way of private placement to Malaysian institutional and selected investors.
Sandy Tan, chief executive officer of Optimax, said at the prospectus launch that the Company’s listing is an important milestone since its founding 25 years ago.
“This journey continues with our plans to expand our ambulatory care centre network in Malaysia, including to areas where we do not have a market presence.” “For a start, our immediate plans will be to expand our ambulatory care centre network in the Central region of Peninsular Malaysia.
This addresses the potential needs of urban communities in this densely populated region.
“Part of the proceeds from the IPO will go towards equipping our Seremban specialist centre and purchasing the property to convert this centre to an ambulatory care centre.
“We are also purchasing new equipment and tools for existing centres as part of plans to upgrade the equipment as well as increase our services and expand our capacity.” To date, the Company has 13 eye specialist centres spread across the Northern, Central and Southern regions of Peninsular Malaysia as well as East Malaysia, and comprises one specialist hospital, 11 ambulatory care centres and one specialist clinic.
These centres are either fully-owned or jointly-owned with resident eye surgeons.
Optimax’s team of specialists comprise 18 eye surgeons and 33 optometrists.
The gross proceeds from the IPO, which is expected to raise RM21.00 million, will be utilised for capital expenditure, repayment of borrowings, working capital and estimated listing expenses.
Optimax’s principal adviser, sole placement agent, sole underwriter and sponsor in relation to the IPO is Affin Hwang Investment Bank Berhad (AffinHwang IB).
Pursuant to the underwriting agreement, AffinHwang IB will be underwriting 17.50 million shares comprising the 13.50 million shares made available for the Malaysian public and the four million shares made available for eligible directors and employees of Optimax.